Quick Facts

• Chronic Constipation: May facilitate the occurrence of bowel movements and soften the stool consistency.
• Hepatic Encephalopathy (HE): Used for the management and prevention of this neurological complication associated with liver disease.

Lactulosum Hasco is a medication containing the active substance lactulose. It is used to manage two main therapeutic areas based on clinical indications and official guidance.

The primary use is for the symptomatic treatment of chronic constipation. Lactulose may help to increase the water content in the stool, which contributes to a softer stool consistency and can facilitate increased bowel action. This action is beneficial for individuals experiencing difficulty with regular bowel movements.

Additionally, this treatment is indicated for the management of portal-systemic encephalopathy (PSE), often referred to as hepatic encephalopathy (HE). In this context, it may serve as an adjunct therapy to help reduce elevated blood ammonia levels, which are associated with this condition. Its use for this purpose is aligned with established treatment protocols to help improve the patient's mental state and reduce the severity of symptoms.

Regulatory References

1. NIH MedlinePlus guidance

Who Can and Cannot Use Lactulosum Hasco?

Population eligibility for Lactulosum Hasco (Lactulose solution) is strictly defined by government regulatory documents, outlining those groups who are permitted, restricted, or prohibited from using the medicine.

---

Absolute Contraindications (Must Not Use)

Lactulosum Hasco is strictly contraindicated for patients with galactosaemia (a genetic metabolic disorder) or those requiring a low-galactose diet. Use is also prohibited for individuals with a known or suspected gastrointestinal obstruction, perforation, or risk of perforation, or a documented hypersensitivity to lactulose or its excipients. Total lactase deficiency or glucose-galactose malabsorption also constitutes an exclusion.

Populations Requiring Conditional Use

Population Group	Regulatory Status
Pediatric Patients	Use of laxatives should be exceptional and under medical supervision. Safety and efficacy for hepatic encephalopathy (HE) are not established in this age group.
Pregnant/Breastfeeding	Use is permitted or may be considered if clearly needed, as systemic exposure is negligible.
Diabetics	Use with caution; the sugar content must be considered, particularly with high doses.
Older Adults	No special dosage exists, but periodic control of serum electrolytes is indicated for long-term users (over six months) in bad general condition.

---

Use in patients with renal or hepatic impairment is permitted without special dosage recommendations. Treatment for painful abdominal symptoms of undetermined cause must be preceded by a medical evaluation to rule out obstruction.

Interactions with other medicines and products

Official regulatory documents describe interactions with Lactulosum Hasco (Lactulose) that primarily affect electrolyte balance or the product's efficacy within the colon.

Pharmacodynamic Interactions

Co-administration with potassium-losing agents may increase the risk of potassium depletion. These agents include certain thiazides, corticosteroids, and amphotericin B. The resulting potassium deficiency may consequently increase the effect, or toxicity, of cardiac glycosides such as digoxin.

Efficacy-Related Interactions

Interactions that may reduce the therapeutic effect of Lactulosum Hasco are documented.

• Nonabsorbable Antacids: These substances may inhibit the intended pH reduction in the colon, which is essential for the product's action. This can lead to a possible lack of desired effect.
• Oral Anti-infective Agents: Certain anti-infective agents, such as neomycin, may theoretically interfere with the degradation of Lactulose by eliminating the necessary colonic bacteria, thereby preventing the required acidification of colonic contents.

Procedure-Related Restrictions

Regulatory labeling specifies a constraint related to medical procedures. A theoretical hazard exists for patients undergoing electrocautery procedures (like proctoscopy or colonoscopy) due to the accumulation of metabolically produced hydrogen gas. A thorough bowel cleansing with a non-fermentable solution is required prior to the procedure.

How Lactulosum Hasco Works: Mechanism of Action

Lactulosum Hasco (Lactulose) acts purely within the colon, relying entirely on the local microbial environment without systemic absorption or interaction with human host receptors. The mechanism is initiated by colonic bacteria through the metabolism of the unabsorbed lactulose, yielding short-chain organic acids.

This metabolism establishes an osmotic gradient, causing the movement of water into the intestinal lumen. The resulting fluid volume increase reduces the viscosity of the contents and mechanically distends the colon wall, thereby stimulating peristalsis to accelerate the transit of contents.

Simultaneously, the production of organic acids lowers the colonic pH (acidification). This acidic environment chemically converts free, absorbable ammonia ( NH3) into the non-absorbable ammonium ion ( NH4^+), a process known as ion trapping. The charged NH4^+ is then physically expelled with the stool, preventing its re-entry into the bloodstream, consistent with the physiological clearance of nitrogenous waste.

The administration of Lactulosum Hasco, which contains the active substance lactulose, follows established clinical protocols. The primary and standard route of administration for this medicine is oral as a solution or syrup. An alternative rectal route, using a diluted solution as a retention enema, is used for the initial management of acute hepatic encephalopathy (HE) when oral intake is compromised.

Dosing regimens are distinct for each approved use. For the symptomatic treatment of chronic constipation, adults typically begin with a starting dose range of 15 mL to 45 mL daily, which may be taken once daily or divided into two doses. This is subsequently adjusted to a lower maintenance dose of 15 mL to 30 mL based on the individual response.

In the management of Hepatic Encephalopathy, the initial oral regimen is more intensive, generally starting at 30 mL to 45 mL three to four times daily. The fundamental goal of the maintenance dose is to be continuously adjusted (titrated) to achieve a clinical endpoint of two or three soft stools daily.

Regarding intake conditions, the solution may be administered undiluted or mixed with water, fruit juice, or milk to improve palatability. When a single daily dose is prescribed, it should be consumed at the same time each day, such as with breakfast, and the entire dose should be swallowed in one go. Treatment for HE typically requires continuous long-term therapy, whereas use for chronic constipation may be short-term.

Research Evidence: Overview of Studies

Lactulose is a synthetic sugar molecule that is not absorbed into the bloodstream. Clinical studies have focused on its use in constipation and in hepatic encephalopathy (HE), a neurological complication of severe liver disease.

Mechanism of Action (How it Works)

Research suggests that lactulose passes through the stomach and small intestine largely unchanged, reaching the colon where it is metabolized by intestinal bacteria. This process results in the production of organic acids, primarily lactic acid and acetic acid. This fermentation achieves two key effects that have been examined in research:

1. Osmotic Effect: The resulting metabolites draw water into the colon, which softens stool and promotes peristalsis (bowel movement), leading to a laxative effect.
2. Ammonia Reduction: In the context of HE, the acidic environment created in the colon converts ammonia ( NH3) into ammonium ions ( NH4^+). Since ammonium ions are poorly absorbed into the blood, this process traps the ammonia within the colon, allowing it to be excreted via feces, thus reducing systemic ammonia levels.

Clinical Efficacy Summary

Condition	Research Findings	Notes on Evidence
Chronic Constipation	Randomized controlled trials (RCTs) confirm the osmotic action aids in softening stool and increasing the frequency of bowel movements compared to placebo.	Often considered a first-line treatment due to its established osmotic and prebiotic effects.
Hepatic Encephalopathy (HE)	Multiple studies, including RCTs, show that lactulose is associated with a reduction in blood ammonia levels and an improvement in mental status in patients with HE.	Lactulose is widely considered a standard of care for the treatment and prevention of recurrent HE episodes.

Combination Therapy

Studies have also explored the effects of lactulose when combined with certain antibiotics, such as rifaximin, for the treatment of HE. Meta-analyses of these trials indicate that the combination of rifaximin plus lactulose may be associated with an increased rate of clinical improvement and a potential reduced risk of mortality when compared to lactulose used alone.

Common questions about Lactulosum Hasco (FAQ)

---

Q: Is Lactulosum Hasco the same as other lactulose products?

Lactulosum Hasco contains the active substance lactulose, which is the same core ingredient found in other lactulose products. However, official product information indicates that the solution may contain small, residual amounts of other sugars, such as lactose and galactose, due to the manufacturing process. These minor components can sometimes vary between specific brands.

Q: How does Lactulosum Hasco compare to senna or bisacodyl?

Lactulose works by an osmotic mechanism, meaning it draws water into the colon through a physical process. This is different from stimulant laxatives, such as senna or bisacodyl, which are designed to directly stimulate the muscles of the intestine to increase contractions. This difference in mechanism is how they are classified in official sources.

Q: Can Lactulosum Hasco cause stomach cramps?

Yes, stomach or abdominal cramps are listed among the possible side effects in regulatory documents, alongside other common gastrointestinal effects like gas and a bloated feeling. These effects are generally described as mild, especially when the medicine is first started.

Q: Can people with lactose intolerance take Lactulosum Hasco?

Official information notes that lactulose contains trace amounts of other sugars, including lactose and galactose. Because of this, it is described as generally not suitable for individuals who are following a strict low-galactose diet, and a regulatory caution is noted for individuals with severe lactose intolerance.

Q: Can Lactulosum Hasco affect blood sugar levels?

Caution is noted in regulatory guidelines for patients with diabetes or high blood sugar. Although the primary ingredient (lactulose) is not significantly absorbed into the bloodstream, the final product may contain trace amounts of other sugars that may be relevant for individuals monitoring their glucose levels.

Q: Is Lactulosum Hasco approved for use in infants?

Official guidelines indicate that lactulose may be used in infants and children of all ages, including babies aged 1 month to 11 months. However, official information states that the use in patients under 14 years old is often supervised by a healthcare professional.

Q: Can older adults use Lactulosum Hasco safely?

Official warnings indicate that caution is advised for older adults (aged 65 years and older) using this medicine. This age group may have an increased risk of certain side effects. In particular, regulatory texts note that severe diarrhea can lead to fluid and electrolyte imbalances in older or acutely ill patients.

Q: Is Lactulosum Hasco an opioid or habit-forming?

Lactulose is not an opioid medicine. Furthermore, regulatory documents that address the risks associated with prolonged use do not list dependence or addiction potential as known risks associated with its mechanism or use.

Q: Is Lactulosum Hasco safe for long-term use?

Long-term, continuous therapy is sometimes required, particularly for conditions like hepatic encephalopathy. Regulatory documents describe the need for blood work monitoring when used long-term, due to the risk of electrolyte imbalances.

Q: What are the most common side effects of Lactulosum Hasco?

The most commonly reported side effects, especially when first starting treatment, include very common effects like diarrhoea (particularly at high doses), bloating, and gas (flatulence). Official information describes these effects as generally mild and temporary.

Q: What is the difference between Lactulosum Hasco and a fiber supplement?

Lactulose is classified as an osmotic laxative that chemically draws water into the colon. This differs from most fiber supplements, which are classified as bulk-forming laxatives that increase stool mass through non-digestible material to promote a bowel movement.

Q: What if I forget to take Lactulosum Hasco at the usual time?

Official regulatory guidance addresses how to handle a missed dose in relation to the next scheduled dose, detailing conditions under which a missed dose may be taken later or should be skipped. Specific dosing instructions are contained within the core product labeling.

Q: Is Lactulosum Hasco safe for pregnant women to use?

According to official product information, lactulose is generally acceptable for use during pregnancy. This is because the medicine is not significantly absorbed into the bloodstream, meaning exposure to the developing fetus is minimal.

Q: Can taking Lactulosum Hasco cause diarrhea?

Yes, diarrhea is a recognized and common side effect, especially when higher doses are used. Regulatory information notes that if diarrhea occurs, it is an indication that the dosage may need adjustment.

Q: What if the usual expected time for effect passes and nothing happens?

Because the medicine requires time to reach the colon and be metabolized, the desired effect may require 24 to 48 hours to occur. Regulatory guidance for chronic use often involves adjusting the dose over several days until a specific clinical goal is pursued.

Q: Does Lactulosum Hasco require refrigeration after opening?

Regulatory documents recommend storing the solution at controlled room temperature, typically between 15° to 30°C (59° to 86°F), and warn against freezing. The medicine does not typically require refrigeration for storage.

Q: Can Lactulosum Hasco be used for chronic constipation?

Yes, the medicine is officially indicated for the treatment of constipation in patients who experience chronic (long-lasting) symptoms. Its use and dose for this purpose are guided by official regulatory guidelines.

Q: What should I do if I experience unexpected effects from Lactulosum Hasco?

Official regulatory guidance encourages reporting unexpected or concerning effects to a healthcare professional. Regulatory bodies also provide systems for patients to report side effects directly after taking the medicine.

Q: Why is Lactulosum Hasco sometimes used in hospital settings?

In hospital settings, this medicine may be administered rectally as a retention enema using a diluted solution. This is an approved route of administration for the initial, acute management of hepatic encephalopathy when a person cannot take the medicine orally.

Storage and Disposal of Lactulosum Hasco

The official labeling for Lactulose Solution defines specific storage and disposal requirements to maintain product quality.

Storage Conditions

Requirement	Details
Temperature	Store at controlled room temperature (20 to 25 C / 68 to 77 F). Do not freeze. Avoid prolonged exposure above 30 C
Protection	Keep the container tightly closed and protected from direct light.
Stability Note	Do not use if extreme darkening and turbidity develop. Normal darkening is acceptable.
Child Safety	Must be kept out of the sight and reach of children.

Disposal

Unused or expired Lactulosum Hasco must be disposed of in accordance with local requirements for pharmaceutical waste.